Minovia Drug MNV-201 Receives FDA Orphan Drug Designation
Minovia Therapeutics has secured FDA Orphan Drug Designation for MNV-201 in myelodysplastic syndromes, adding to the asset’s existing Fast...
AI Drug Discovery AstraZeneca BIO-Europe Spring 2026 biopharma M&A biopharma strategy biotech funding biotech strategy business development cancer immunotherapy China Biotech CNS Pipeline Strategy competitive intelligence Disease-Modifying Therapy Drug Pricing Strategy eClinical Tech News Eli Lilly Emerging Markets FDA Approval FDA Priority Review HER2 Oncology immuno-oncology immunology licensing deals Lifecycle Management Market Access Medtronic MSS colorectal cancer Novo Nordisk Obesity/GLP-1 Obesity Drug Market Obesity Market Oncology Pipeline Patent Cliff Priority Review Voucher pulmonary hypertension Rare Disease Regeneron respiratory biologics Roche Sanofi series A funding Teva Pharmaceuticals Type 1 Diabetes Type 2 Diabetes venture capital
No videos found.
Minovia Therapeutics has secured FDA Orphan Drug Designation for MNV-201 in myelodysplastic syndromes, adding to the asset’s existing Fast...
60 Degrees Pharmaceuticals reported the first negative post-treatment result in its expanded access study of tafenoquine for relapsing babesiosis...
Regeneron will present seven oncology abstracts at ESMO 2025, led by new Phase 3 C-POST safety and pharmacokinetic data...
Bexorg has closed a $23 million Series A led by Engine Ventures, bringing total funding to $42.5 million to...
Biodesix will present interim real-world data from the Clarify study at the 2025 CHEST Annual Meeting in Chicago, including...
Argenx is using the AANEM Annual Meeting and MGFA Scientific Session to widen the runway for its neuromuscular franchise....
BioCryst Pharmaceuticals is acquiring Astria Therapeutics in a cash-and-stock deal valuing Astria at an implied $13.00 per share, or...
Assembly Biosciences will host fireside chats at two investor forums: the H.C. Wainwright Liver Disease Virtual Conference on October...
Adlai Nortye will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on...
PMV Pharmaceuticals will deliver the first look at initial data from its pivotal Phase 2 PYNNACLE study of rezatapopt...
